Diabetes & Metabolism Journal

Original Articles

Cardiovascular Risk/Epidemiology
Comparative Effects of Sodium-Glucose Cotransporter 2 Inhibitor and Thiazolidinedione Treatment on Risk of Stroke among Patients with Type 2 Diabetes Mellitus: Seung Eun Lee, Hyewon Nam, Han Seok Choi, Hoseob Kim, Dae-Sung Kyoung, Kyoung-Ah Kim; Diabetes Metab J. 2022;46(4):567-577. Published online February 8, 2022; DOI: https://doi.org/10.4093/dmj.2021.0160

6,811 View
390 Download
7 Web of Science
8 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
Although cardiovascular outcome trials using sodium-glucose cotransporter-2 inhibitors (SGLT-2i) showed a reduction in risk of 3-point major adverse cardiovascular events (MACE), they did not demonstrate beneficial effects on stroke risk. Additionally, meta-analysis showed SGLT-2i potentially had an adverse effect on stroke risk. Contrarily, pioglitazone, a type of thiazolidinedione (TZD), has been shown to reduce recurrent stroke risk. Thus, we aimed to compare the effect of SGLT-2i and TZD on the risk of stroke in type 2 diabetes mellitus (T2DM) patients.
Methods
Using the Korean National Health Insurance Service data, we compared a 1:1 propensity score-matched cohort of patients who used SGLT-2i or TZD from January 2014 to December 2018. The primary outcome was stroke. The secondary outcomes were myocardial infarction (MI), cardiovascular death, 3-point MACE, and heart failure (HF).
Results
After propensity-matching, each group included 56,794 patients. Baseline characteristics were well balanced. During the follow-up, 862 patients were newly hospitalized for stroke. The incidence rate of stroke was 4.11 and 4.22 per 1,000 person-years for the TZD and SGLT-2i groups respectively. The hazard ratio (HR) of stroke was 1.054 (95% confidence interval [CI], 0.904 to 1.229) in the SGLT-2i group compared to the TZD group. There was no difference in the risk of MI, cardiovascular death, 3-point MACE between groups. Hospitalization for HF was significantly decreased in SGLT-2i-treated patients (HR, 0.645; 95% CI, 0.466 to 0.893). Results were consistent regardless of prior cardiovascular disease.
Conclusion
In this real-world data, the risk of stroke was comparable in T2DM patients treated with SGLT-2i or TZD.

Citations

Citations to this article as recorded by

Similar incidence of stroke with SGLT2 inhibitors and GLP-1 receptor agonists in real-world cohort studies among patients with type 2 diabetes
André J. Scheen
Diabetes Epidemiology and Management.2024; 13: 100179. CrossRef
Diabetes and Stroke: Impact of Novel Therapies for the Treatment of Type 2 Diabetes Mellitus
Inês Henriques Vieira, Tânia Santos Carvalho, Joana Saraiva, Leonor Gomes, Isabel Paiva
Biomedicines.2024; 12(5): 1102. CrossRef
Key results from observational studies and real‐world evidence of sodium‐glucose cotransporter‐2 inhibitor effectiveness and safety in reducing cardio‐renal risk
Thomas Nyström
Diabetes, Obesity and Metabolism.2024; 26(S5): 35. CrossRef
Comparison of Statin With Ezetimibe Combination Therapy Versus Statin Monotherapy for Primary Prevention in Middle-Aged Adults
Jung-Joon Cha, Soon Jun Hong, Subin Lim, Ju Hyeon Kim, Hyung Joon Joo, Jae Hyoung Park, Cheol Woong Yu, Do-Sun Lim, Jang Young Kim, Jin-Ok Jeong, Jeong-Hun Shin, Chi Young Shim, Jong-Young Lee, Young-Hyo Lim, Sung Ha Park, Eun Joo Cho, Hasung Kim, Jungkuk
Korean Circulation Journal.2024; 54(9): 534. CrossRef
A Green Approach: Optimization of the UPLC Method Using DoE Software for Concurrent Quantification of Pioglitazone and Dapagliflozin in a SNEDDS Formulation for the Treatment of Diabetes
Ehab M. Elzayat, Abdelrahman Y. Sherif, Mohamed W. Attwa, Mohammad A. Altamimi
ACS Omega.2024; 9(45): 45011. CrossRef
Cardiovascular Disease & Diabetes Statistics in Korea: Nationwide Data 2010 to 2019
Jin Hwa Kim, Junyeop Lee, Kyungdo Han, Jae-Taek Kim, Hyuk-Sang Kwon
Diabetes & Metabolism Journal.2024; 48(6): 1084. CrossRef
Lobeglitazone, a novel thiazolidinedione, for secondary prevention in patients with ischemic stroke: a nationwide nested case-control study
Joonsang Yoo, Jimin Jeon, Minyoul Baik, Jinkwon Kim
Cardiovascular Diabetology.2023;[Epub] CrossRef
Do SGLT2 inhibitors and GLP-1 receptor agonists modulate differently the risk of stroke ? Discordance between randomised controlled trials and observational studies
André J. Scheen
Diabetes & Metabolism.2023; 49(5): 101474. CrossRef

COVID-19
Effects of a DPP-4 Inhibitor and RAS Blockade on Clinical Outcomes of Patients with Diabetes and COVID-19: Sang Youl Rhee, Jeongwoo Lee, Hyewon Nam, Dae-Sung Kyoung, Dong Wook Shin, Dae Jung Kim; Diabetes Metab J. 2021;45(2):251-259. Published online March 5, 2021; DOI: https://doi.org/10.4093/dmj.2020.0206

9,015 View
415 Download
34 Web of Science
35 Crossref

Graphical Abstract Abstract PDF Supplementary Material PubReader ePub

Background
Dipeptidyl peptidase-4 inhibitor (DPP-4i) and renin-angiotensin system (RAS) blockade are reported to affect the clinical course of coronavirus disease 2019 (COVID-19) in patients with diabetes mellitus (DM).
Methods
As of May 2020, analysis was conducted on all subjects who could confirm their history of claims related to COVID-19 in the National Health Insurance Review and Assessment Service (HIRA) database in Korea. Using this dataset, we compared the short-term prognosis of COVID-19 infection according to the use of DPP-4i and RAS blockade. Additionally, we validated the results using the National Health Insurance Service (NHIS) of Korea dataset.
Results
Totally, data of 67,850 subjects were accessible in the HIRA dataset. Of these, 5,080 were confirmed COVID-19. Among these, 832 subjects with DM were selected for analysis in this study. Among the subjects, 263 (31.6%) and 327 (39.3%) were DPP4i and RAS blockade users, respectively. Thirty-four subjects (4.09%) received intensive care or died. The adjusted odds ratio for severe treatment among DPP-4i users was 0.362 (95% confidence interval [CI], 0.135 to 0.971), and that for RAS blockade users was 0.599 (95% CI, 0.251 to 1.431). These findings were consistent with the analysis based on the NHIS data using 704 final subjects. The adjusted odds ratio for severe treatment among DPP-4i users was 0.303 (95% CI, 0.135 to 0.682), and that for RAS blockade users was 0.811 (95% CI, 0.391 to 1.682).
Conclusion
This study suggests that DPP-4i is significantly associated with a better clinical outcome of patients with COVID-19.

Citations

Citations to this article as recorded by

Potential use of plant-based therapeutics for the management of SARS-COV2 infection in Diabetes mellitus- A review
Neha Deora, Krishnan Venkatraman
Journal of Herbal Medicine.2024; : 100923. CrossRef
The Impact of GLP-1 RAs and DPP-4is on Hospitalisation and Mortality in the COVID-19 Era: A Two-Year Observational Study
Salvatore Greco, Vincenzo M. Monda, Giorgia Valpiani, Nicola Napoli, Carlo Crespini, Fabio Pieraccini, Anna Marra, Angelina Passaro
Biomedicines.2023; 11(8): 2292. CrossRef
Efficacy and Safety of Sitagliptin in the Treatment of COVID-19
Ehab Mudher Mikhael, Siew Chin Ong, Siti Maisharah Sheikh Ghadzi
Journal of Pharmacy Practice.2023; 36(4): 980. CrossRef
DPP-4 Inhibitors as a Savior for COVID-19 Patients with Diabetes
Snehasish Nag, Samanwita Mandal, Oindrila Mukherjee, Suprabhat Mukherjee, Rakesh Kundu
Future Virology.2023; 18(5): 321. CrossRef
Risk phenotypes of diabetes and association with COVID-19 severity and death: an update of a living systematic review and meta-analysis
Sabrina Schlesinger, Alexander Lang, Nikoletta Christodoulou, Philipp Linnerz, Kalliopi Pafili, Oliver Kuss, Christian Herder, Manuela Neuenschwander, Janett Barbaresko, Michael Roden
Diabetologia.2023; 66(8): 1395. CrossRef
ACE2, ACE, DPPIV, PREP and CAT L enzymatic activities in COVID-19: imbalance of ACE2/ACE ratio and potential RAAS dysregulation in severe cases
Raquel Leão Neves, Jéssica Branquinho, Júlia Galanakis Arata, Clarissa Azevedo Bittencourt, Caio Perez Gomes, Michelle Riguetti, Gustavo Ferreira da Mata, Danilo Euclides Fernandes, Marcelo Yudi Icimoto, Gianna Mastroianni Kirsztajn, João Bosco Pesquero
Inflammation Research.2023; 72(8): 1719. CrossRef
Association Between Anti-diabetic Agents and Clinical Outcomes of COVID-19 in Patients with Diabetes: A Systematic Review and Meta-Analysis
Tiantian Han, Shaodi Ma, Chenyu Sun, Huimei Zhang, Guangbo Qu, Yue Chen, Ce Cheng, Eric L. Chen, Mubashir Ayaz Ahmed, Keun Young Kim, Raveena Manem, Mengshi Chen, Zhichun Guo, Hongru Yang, Yue Yan, Qin Zhou
Archives of Medical Research.2022; 53(2): 186. CrossRef
Use of DPP4i reduced odds of clinical deterioration and hyperinflammatory syndrome in COVID-19 patients with type 2 diabetes: Propensity score analysis of a territory-wide cohort in Hong Kong
Carlos K.H. Wong, David T.W. Lui, Angel Y.C. Lui, Ashley C.Y. Kwok, Marshall C.H. Low, Kristy T.K. Lau, Ivan C.H. Au, Xi Xiong, Matthew S.H. Chung, Eric H.Y. Lau, Benjamin J. Cowling
Diabetes & Metabolism.2022; 48(1): 101307. CrossRef
Dipeptidyl peptidase-4 (DPP-IV) inhibitor was associated with mortality reduction in COVID-19 — A systematic review and meta-analysis
Ahmad Fariz Malvi Zamzam Zein, Wilson Matthew Raffaello
Primary Care Diabetes.2022; 16(1): 162. CrossRef
Mortality and Severity in COVID-19 Patients on ACEIs and ARBs—A Systematic Review, Meta-Analysis, and Meta-Regression Analysis
Romil Singh, Sawai Singh Rathore, Hira Khan, Abhishek Bhurwal, Mack Sheraton, Prithwish Ghosh, Sohini Anand, Janaki Makadia, Fnu Ayesha, Kiran S. Mahapure, Ishita Mehra, Aysun Tekin, Rahul Kashyap, Vikas Bansal
Frontiers in Medicine.2022;[Epub] CrossRef
Short- and long-term prognosis of glycemic control in COVID-19 patients with type 2 diabetes
K Zhan, X Zhang, B Wang, Z Jiang, X Fang, S Yang, H Jia, L Li, G Cao, K Zhang, X Ma
QJM: An International Journal of Medicine.2022; 115(3): 131. CrossRef
Decreased Circulating Dipeptidyl Peptidase-4 Enzyme Activity Is Prognostic for Severe Outcomes in Covid-19 Inpatients
Ákos Nádasdi, György Sinkovits, Ilona Bobek, Botond Lakatos, Zsolt Förhécz, Zita Z Prohászka, Marienn Réti, Miklós Arató, Gellért Cseh, Tamás Masszi, Béla Merkely, Péter Ferdinandy, István Vályi-Nagy, Zoltán Prohászka, Gábor Firneisz
Biomarkers in Medicine.2022; 16(5): 317. CrossRef
Management von Diabetespatienten in der COVID-19-Pandemie
Charlotte Steenblock, Carlotta Hoffmann, Tilman D. Rachner, Florian Guggenbichler, Ermal Tahirukaj, Sacipi Bejtullah, Vsevolod A. Zinserling, Zsuzanna Varga, Stefan R. Bornstein, Nikolaos Perakakis
Diabetes aktuell.2022; 20(01): 43. CrossRef
Letter: Diabesity Associates with Poor COVID-19 Outcomes among Hospitalized Patients (J Obes Metab Syndr 2021;30:149-54)
Tae Jung Oh
Journal of Obesity & Metabolic Syndrome.2022; 31(1): 86. CrossRef
Glucose-Lowering Agents and COVID-19
Ah Reum Khang
The Journal of Korean Diabetes.2022; 23(1): 1. CrossRef
The Association Between Antidiabetic Agents and Clinical Outcomes of COVID-19 Patients With Diabetes: A Bayesian Network Meta-Analysis
Yidan Chen, Xingfei Lv, Sang Lin, Mohammad Arshad, Mengjun Dai
Frontiers in Endocrinology.2022;[Epub] CrossRef
Drug-Disease Severity and Target-Disease Severity Interaction Networks in COVID-19 Patients
Verena Schöning, Felix Hammann
Pharmaceutics.2022; 14(9): 1828. CrossRef
Role of Dipeptidyl Peptidase-4 (DPP4) on COVID-19 Physiopathology
Alba Sebastián-Martín, Belén G. Sánchez, José M. Mora-Rodríguez, Alicia Bort, Inés Díaz-Laviada
Biomedicines.2022; 10(8): 2026. CrossRef
Anti-Diabetic Drugs GLP-1 Agonists and DPP-4 Inhibitors may Represent Potential Therapeutic Approaches for COVID-19
Aliah Alshanwani, Tarek Kashour, Amira Badr
Endocrine, Metabolic & Immune Disorders - Drug Targets.2022; 22(6): 571. CrossRef
Dipeptidyl peptidase 4 inhibitors in COVID-19: Beyond glycemic control
Niya Narayanan, Dukhabandhu Naik, Jayaprakash Sahoo, Sadishkumar Kamalanathan
World Journal of Virology.2022; 11(6): 399. CrossRef
Associations Between the Use of Renin–Angiotensin System Inhibitors and the Risks of Severe COVID-19 and Mortality in COVID-19 Patients With Hypertension: A Meta-Analysis of Observational Studies
Xiao-Ce Dai, Zhuo-Yu An, Zi-Yang Wang, Zi-Zhen Wang, Yi-Ren Wang
Frontiers in Cardiovascular Medicine.2021;[Epub] CrossRef
Risk phenotypes of diabetes and association with COVID-19 severity and death: a living systematic review and meta-analysis
Sabrina Schlesinger, Manuela Neuenschwander, Alexander Lang, Kalliopi Pafili, Oliver Kuss, Christian Herder, Michael Roden
Diabetologia.2021; 64(7): 1480. CrossRef
Protecting older patients with cardiovascular diseases from COVID-19 complications using current medications
Mariana Alves, Marília Andreia Fernandes, Gülistan Bahat, Athanase Benetos, Hugo Clemente, Tomasz Grodzicki, Manuel Martínez-Sellés, Francesco Mattace-Raso, Chakravarthi Rajkumar, Andrea Ungar, Nikos Werner, Timo E. Strandberg, Grodzicki, Strandberg
European Geriatric Medicine.2021; 12(4): 725. CrossRef
Cardiometabolic Therapy and Mortality in Very Old Patients With Diabetes Hospitalized due to COVID-19
Jose Manuel Ramos-Rincón, Luis M Pérez-Belmonte, Francisco Javier Carrasco-Sánchez, Sergio Jansen-Chaparro, Mercedes De-Sousa-Baena, José Bueno-Fonseca, Maria Pérez-Aguilar, Coral Arévalo-Cañas, Marta Bacete Cebrian, Manuel Méndez-Bailón, Isabel Fiteni Me
The Journals of Gerontology: Series A.2021; 76(8): e102. CrossRef
Managing diabetes in diabetic patients with COVID: where do we start from?
Angelo Avogaro, Benedetta Bonora, Gian Paolo Fadini
Acta Diabetologica.2021; 58(11): 1441. CrossRef
The SARS-CoV-2 receptor angiotensin-converting enzyme 2 (ACE2) in myalgic encephalomyelitis/chronic fatigue syndrome: A meta-analysis of public DNA methylation and gene expression data
João Malato, Franziska Sotzny, Sandra Bauer, Helma Freitag, André Fonseca, Anna D. Grabowska, Luís Graça, Clara Cordeiro, Luís Nacul, Eliana M. Lacerda, Jesus Castro-Marrero, Carmen Scheibenbogen, Francisco Westermeier, Nuno Sepúlveda
Heliyon.2021; 7(8): e07665. CrossRef
Effects of a DPP-4 Inhibitor and RAS Blockade on Clinical Outcomes of Patients with Diabetes and COVID-19 (Diabetes Metab J 2021;45:251-9)
Sang Youl Rhee
Diabetes & Metabolism Journal.2021; 45(4): 619. CrossRef
Effects of a DPP-4 Inhibitor and RAS Blockade on Clinical Outcomes of Patients with Diabetes and COVID-19 (Diabetes Metab J 2021;45:251-9)
Guntram Schernthaner
Diabetes & Metabolism Journal.2021; 45(4): 615. CrossRef
COVID-19 and metabolic disease: mechanisms and clinical management
Charlotte Steenblock, Peter E H Schwarz, Barbara Ludwig, Andreas Linkermann, Paul Zimmet, Konstantin Kulebyakin, Vsevolod A Tkachuk, Alexander G Markov, Hendrik Lehnert, Martin Hrabě de Angelis, Hannes Rietzsch, Roman N Rodionov, Kamlesh Khunti, David Hop
The Lancet Diabetes & Endocrinology.2021; 9(11): 786. CrossRef
Diabetes, Obesity, and COVID-19
Sang Youl Rhee
The Journal of Korean Diabetes.2021; 22(3): 174. CrossRef
Sunlight Exposure and Phototherapy: Perspectives for Healthy Aging in an Era of COVID-19
Toshiaki Nakano, Kuei-Chen Chiang, Chien-Chih Chen, Po-Jung Chen, Chia-Yun Lai, Li-Wen Hsu, Naoya Ohmori, Takeshi Goto, Chao-Long Chen, Shigeru Goto
International Journal of Environmental Research and Public Health.2021; 18(20): 10950. CrossRef
Analysis of influence of background therapy for comorbidities in the period before infection on the risk of the lethal COVID outcome. Data from the international ACTIV SARS-CoV-2 registry («Analysis of chronic non-infectious diseases dynamics after COVID-
E. I. Tarlovskaya, A. G. Arutyunov, A. O. Konradi, Yu. M. Lopatin, A. P. Rebrov, S. N. Tereshchenko, A. I. Chesnikova, H. G. Hayrapetyan, A. P. Babin, I. G. Bakulin, N. V. Bakulina, L. A. Balykova, A. S. Blagonravova, M. V. Boldina, A. R. Vaisberg, A. S.
Kardiologiia.2021; 61(9): 20. CrossRef
Association of clinical characteristics, antidiabetic and cardiovascular agents with diabetes mellitus and COVID-19: a 7-month follow-up cohort study
Marzieh Pazoki, Fatemeh Chichagi, Azar Hadadi, Samira Kafan, Mahnaz Montazeri, Sina Kazemian, Arya Aminorroaya, Mehdi Ebrahimi, Haleh Ashraf, Mojgan Mirabdolhagh Hazaveh, Mohammad Reza Khajavi, Reza Shariat Moharari, Seyed Hamidreza Sharifnia, Shahrokh Ka
Journal of Diabetes & Metabolic Disorders.2021; 20(2): 1545. CrossRef
COVID-19 and Diabetes: A Comprehensive Review of Angiotensin Converting Enzyme 2, Mutual Effects and Pharmacotherapy
Lingli Xie, Ziying Zhang, Qian Wang, Yangwen Chen, Dexue Lu, Weihua Wu
Frontiers in Endocrinology.2021;[Epub] CrossRef
The Roles of Dipeptidyl Peptidase 4 (DPP4) and DPP4 Inhibitors in Different Lung Diseases: New Evidence
Tianli Zhang, Xiang Tong, Shijie Zhang, Dongguang Wang, Lian Wang, Qian Wang, Hong Fan
Frontiers in Pharmacology.2021;[Epub] CrossRef

First
Prev
Page of 1
Next
Last

Search